Back to search
FDAFDA · Food and drugs·Recall number D-0585-2018

Lynparza (olaparib) capsules 50 mg, 112 count bottles, Rx only, Manufactured for: Astra Zeneca Pharmaceuticals LP Wilmington, DE 19850 by: Patheon Pharmaceuticals, Inc. Cincinnati OH 45237 Product of Switzerland NDC 0310-0657-58

Published March 14, 2018 · Recall initiated: February 23, 2018

Summary

FDA records drug Class III recall D-0585-2018, published March 14, 2018 and initiated February 23, 2018. Recalling firm: AstraZeneca Pharmaceuticals LP; Status: Terminated; Reported quantity: 18056 bottles; Lot: HN0406 02/2018 JH0341 03/2018 JH0342 03/2018 JH0147 03/2018 JC0391 04/2018 JK0147 04/2018 JL0184 04/2018 JC0402 05/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AstraZeneca Pharmaceuticals LP
Distributor
Nationwide
Lot
HN0406 02/2018 JH0341 03/2018 JH0342 03/2018 JH0147 03/2018 JC0391 04/2018 JK0147 04/2018 JL0184 04/2018 JC0402 05/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lynparza (olaparib) capsules 50 mg, 112 count bottles, Rx only, Manufactured for: Astra Zeneca Pharmaceuticals LP Wilmington, DE 19850 by: Patheon Pharmaceuticals, Inc. Cincinnati OH 45237 Product of Switzerland NDC 0310-0657-58 recalled?

Yes. FDA published recall D-0585-2018 on March 14, 2018. Reported hazard: Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).

What should I do if I have this product?

Voluntary: Firm initiated · Letter